http://purl.org/np/RA0S2JEO7jRxcePUbpUK2PN_IhQvKG9hSWyCRjW4OAgt4#Head http://purl.org/np/RA0S2JEO7jRxcePUbpUK2PN_IhQvKG9hSWyCRjW4OAgt4 http://www.nanopub.org/nschema#hasAssertion http://purl.org/np/RA0S2JEO7jRxcePUbpUK2PN_IhQvKG9hSWyCRjW4OAgt4#assertion http://purl.org/np/RA0S2JEO7jRxcePUbpUK2PN_IhQvKG9hSWyCRjW4OAgt4 http://www.nanopub.org/nschema#hasProvenance http://purl.org/np/RA0S2JEO7jRxcePUbpUK2PN_IhQvKG9hSWyCRjW4OAgt4#provenance http://purl.org/np/RA0S2JEO7jRxcePUbpUK2PN_IhQvKG9hSWyCRjW4OAgt4 http://www.nanopub.org/nschema#hasPublicationInfo http://purl.org/np/RA0S2JEO7jRxcePUbpUK2PN_IhQvKG9hSWyCRjW4OAgt4#pubinfo http://purl.org/np/RA0S2JEO7jRxcePUbpUK2PN_IhQvKG9hSWyCRjW4OAgt4 http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.nanopub.org/nschema#Nanopublication http://purl.org/np/RA0S2JEO7jRxcePUbpUK2PN_IhQvKG9hSWyCRjW4OAgt4#assertion http://purl.obolibrary.org/obo/DOID_9538 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Disease http://purl.org/np/RA0S2JEO7jRxcePUbpUK2PN_IhQvKG9hSWyCRjW4OAgt4#association http://www.w3.org/1999/02/22-rdf-syntax-ns#object http://purl.obolibrary.org/obo/DOID_9538 http://purl.org/np/RA0S2JEO7jRxcePUbpUK2PN_IhQvKG9hSWyCRjW4OAgt4#association http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate https://w3id.org/biolink/vocab/treats http://purl.org/np/RA0S2JEO7jRxcePUbpUK2PN_IhQvKG9hSWyCRjW4OAgt4#association http://www.w3.org/1999/02/22-rdf-syntax-ns#subject https://identifiers.org/drugbank:DB08889 http://purl.org/np/RA0S2JEO7jRxcePUbpUK2PN_IhQvKG9hSWyCRjW4OAgt4#association http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement http://purl.org/np/RA0S2JEO7jRxcePUbpUK2PN_IhQvKG9hSWyCRjW4OAgt4#association http://www.w3.org/2000/01/rdf-schema#label kyprolis is a proteasome inhibitor that is indicated in combination with dexamethasone or with lenalidomide plus dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy 1 14 as a single agent for the treatment of patients with relapsed or refractory multiple myeloma who have received one or more lines of therapy 1 14 kyprolis is indicated in combination with dexamethasone or with lenalidomide plus dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy kyprolis is indicated as a single agent for the treatment of patients with relapsed or refractory multiple myeloma who have received one or more lines of therapy http://purl.org/np/RA0S2JEO7jRxcePUbpUK2PN_IhQvKG9hSWyCRjW4OAgt4#association https://w3id.org/biolink/vocab/association_type https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation http://purl.org/np/RA0S2JEO7jRxcePUbpUK2PN_IhQvKG9hSWyCRjW4OAgt4#association https://w3id.org/biolink/vocab/provided_by https://w3id.org/um/NeuroDKG http://purl.org/np/RA0S2JEO7jRxcePUbpUK2PN_IhQvKG9hSWyCRjW4OAgt4#association https://w3id.org/biolink/vocab/relation https://schema.org/TreatmentIndication https://identifiers.org/drugbank:DB08889 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Drug http://purl.org/np/RA0S2JEO7jRxcePUbpUK2PN_IhQvKG9hSWyCRjW4OAgt4#provenance http://purl.org/np/RA0S2JEO7jRxcePUbpUK2PN_IhQvKG9hSWyCRjW4OAgt4#assertion http://www.w3.org/ns/prov#wasAttributedTo https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RA0S2JEO7jRxcePUbpUK2PN_IhQvKG9hSWyCRjW4OAgt4#pubinfo http://purl.org/np/RA0S2JEO7jRxcePUbpUK2PN_IhQvKG9hSWyCRjW4OAgt4#sig http://purl.org/nanopub/x/hasAlgorithm RSA http://purl.org/np/RA0S2JEO7jRxcePUbpUK2PN_IhQvKG9hSWyCRjW4OAgt4#sig http://purl.org/nanopub/x/hasPublicKey MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB http://purl.org/np/RA0S2JEO7jRxcePUbpUK2PN_IhQvKG9hSWyCRjW4OAgt4#sig http://purl.org/nanopub/x/hasSignature NxxsLEtdJs5vMx86r8GDwy5PKJANRgBWxXugAxiVedIKqOYzo1gpCrPeEbmy/zSfwkkJHrl2z5y+FKA9+iLScF4pOthcgmcEFrlHArH1Bw4cIWNkCvfgrLrVzCBOIJsriU28HSV/+2+h+Jbm/D+sNTL3aWmz2oVvDdoVM61t+R0= http://purl.org/np/RA0S2JEO7jRxcePUbpUK2PN_IhQvKG9hSWyCRjW4OAgt4#sig http://purl.org/nanopub/x/hasSignatureTarget http://purl.org/np/RA0S2JEO7jRxcePUbpUK2PN_IhQvKG9hSWyCRjW4OAgt4 http://purl.org/np/RA0S2JEO7jRxcePUbpUK2PN_IhQvKG9hSWyCRjW4OAgt4 http://purl.org/dc/terms/created 2021-06-12T14:54:49.698+02:00 http://purl.org/np/RA0S2JEO7jRxcePUbpUK2PN_IhQvKG9hSWyCRjW4OAgt4 http://purl.org/dc/terms/creator https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RA0S2JEO7jRxcePUbpUK2PN_IhQvKG9hSWyCRjW4OAgt4 https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM http://purl.org/np/RA0S2JEO7jRxcePUbpUK2PN_IhQvKG9hSWyCRjW4OAgt4 https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM http://purl.org/np/RA0S2JEO7jRxcePUbpUK2PN_IhQvKG9hSWyCRjW4OAgt4 https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs